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Abstract
IMPORTANCE Increasing evidence suggests an important role of liver function in the
pathophysiology of Alzheimer disease (AD). The liver is a major metabolic hub; therefore,
investigating the association of liver function with AD, cognition, neuroimaging, and CSF biomarkers
would improve the understanding of the role of metabolic dysfunction in AD.
OBJECTIVE To examine whether liver function markers are associated with cognitive dysfunction
and the “A/T/N” (amyloid, tau, and neurodegeneration) biomarkers for AD.
DESIGN, SETTING, AND PARTICIPANTS In this cohort study, serum-based liver functionmarkers
were measured from September 1, 2005, to August 31, 2013, in 1581 AD Neuroimaging Initiative
participants along with cognitive measures, cerebrospinal fluid (CSF) biomarkers, brain atrophy,
brain glucosemetabolism, and amyloid-β accumulation. Associations of liver functionmarkers with
AD-associated clinical and A/T/N biomarkers were assessed using generalized linear models adjusted
for confounding variables andmultiple comparisons. Statistical analysis was performed from
November 1, 2017, to February 28, 2019.
EXPOSURES Five serum-based liver functionmarkers (total bilirubin, albumin, alkaline
phosphatase, alanine aminotransferase, and aspartate aminotransferase) from ADNeuroimaging
Initiative participants were used as exposure variables.
MAINOUTCOMES ANDMEASURES Primary outcomes included diagnosis of AD, composite scores
for executive functioning andmemory, CSF biomarkers, atrophymeasured bymagnetic resonance
imaging, brain glucose metabolism measured by fludeoxyglucose F 18 (18F) positron emission
tomography, and amyloid-β accumulationmeasured by [18F]florbetapir positron emission
tomography.
RESULTS Participants in the AD Neuroimaging Initiative (n = 1581; 697 women and 884men; mean
[SD] age, 73.4 [7.2] years) included 407 cognitively normal older adults, 20with significantmemory
concern, 298with early mild cognitive impairment, 544 with late mild cognitive impairment, and 312
with AD. An elevated aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio and
lower levels of ALT were associated with AD diagnosis (AST to ALT ratio: odds ratio, 7.932 [95% CI,
1.673-37.617]; P = .03; ALT: odds ratio, 0.133 [95% CI, 0.042-0.422]; P = .004) and poor cognitive
performance (AST to ALT ratio: β [SE], −0.465 [0.180]; P = .02 for memory composite score; β [SE],
−0.679 [0.215]; P = .006 for executive function composite score; ALT: β [SE], 0.397 [0.128];
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Key Points
Question Are liver functionmarkers
associated with cognition and the
“A/T/N” (amyloid, tau, and
neurodegeneration) biomarkers for
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Abstract (continued)
P = .006 for memory composite score; β [SE], 0.637 [0.152]; P < .001 for executive function
composite score). Increased AST to ALT ratio values were associated with lower CSF amyloid-β 1-42
levels (β [SE], −0.170 [0.061]; P = .04) and increased amyloid-β deposition (amyloid biomarkers),
higher CSF phosphorylated tau181 (β [SE], 0.175 [0.055]; P = .02) (tau biomarkers) and higher CSF
total tau levels (β [SE], 0.160 [0.049]; P = .02) and reduced brain glucosemetabolism (β [SE], −0.123
[0.042]; P = .03) (neurodegeneration biomarkers). Lower levels of ALT were associated with
increased amyloid-β deposition (amyloid biomarkers), and reduced brain glucosemetabolism (β
[SE], 0.096 [0.030]; P = .02) and greater atrophy (neurodegeneration biomarkers).
CONCLUSIONS ANDRELEVANCE Consistent associations of serum-based liver functionmarkers
with cognitive performance and A/T/N biomarkers for AD highlight the involvement of metabolic
disturbances in the pathophysiology of AD. Further studies are needed to determine if these
associations represent a causative or secondary role. Liver enzyme involvement in AD opens avenues
for novel diagnostics and therapeutics.
JAMA Network Open. 2019;2(7):e197978. doi:10.1001/jamanetworkopen.2019.7978
Introduction
Metabolic activities in the liver determine the state of themetabolic readout of peripheral circulation.
Mounting evidence suggests that patients with Alzheimer disease (AD) display metabolic
dysfunction.1 Clinical studies suggest that impaired signaling, energy metabolism, inflammation, and
insulin resistance play a role in AD.2,3 This observation is in line with the observation that many
metabolic disorders (eg, diabetes, hypertension, obesity, and dyslipidemia) are risk factors for AD.4
This evidence highlights the importance of the liver in the pathophysiological characteristics of AD.
Focused investigation to assess the role of liver function in AD and its endophenotypes is required to
bridge the gap between these observations.
Peripheral blood levels of biochemical markers including albumin, alkaline phosphatase, alanine
aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin are used to assess liver
function. Alanine aminotransferase and AST are used in general clinical practice to measure liver
injury5,6 and are factors associated with cardiovascular andmetabolic diseases,7,8 known risk factors
of AD and cognitive decline.9,10 Given this fact, it is conceivable that aminotransferases are surrogate
biomarkers of liver metabolic functioning. A systematic search yielded few reports related to
research in humans linking peripheral biomarkers of liver functioning to central biomarkers related to
AD including amyloid-β and tau accumulation, brain glucosemetabolism, and structural atrophy.
We investigated the association of peripheral liver functionmarkers with AD diagnosis,
cognition, and biomarkers of AD pathophysiological characteristics including neuroimaging
(magnetic resonance imaging [MRI] and position emission tomography [PET]) and cerebrospinal
fluid (CSF) from older adults in the AD Neuroimaging Initiative (ADNI) cohort. The AD biomarkers
were selected and defined consistent with the National Institute on Aging–Alzheimer Association
Research Framework (amyloid, tau, and neurodegeneration [A/T/N]) for AD biomarkers that defines
3 general groups of biomarkers based on the nature of pathologic process that eachmeasures.11
Methods
Study Population
Individuals in this study were participants of ADNI. The initial phase (ADNI-1) was launched in 2003
to test whether serial MRI markers, PET markers, other biological markers, and clinical and
neuropsychological assessment could be combined tomeasure the progression of mild cognitive
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impairment (MCI) and early AD. The initial phase was extended to subsequent phases (ADNI-GO,
ADNI-2, and ADNI-3) for follow-up of existing participants and additional new enrollments. Inclusion
and exclusion criteria, clinical and neuroimaging protocols, and other information are reported
elsewhere.12-14 Demographic and clinical information, raw data from neuroimaging scans, CSF
biomarkers, information on APOE status, and cognitive scores were downloaded from the ADNI data
repository.12 Baseline data were collected from September 1, 2005, to August 31, 2013. Written
informed consent was obtained at enrollment, which included permission for analysis and data
sharing. This study was approved by each participating site’s institutional review board. This report
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guidelines for cohort studies.
Liver FunctionMarkers
Five laboratory tests were downloaded from the ADNI data repository and used in the study: total
bilirubin, albumin, alkaline phosphatase, ALT, and AST. The liver function markers followed a normal
distribution after log transformation. For eachmarker, participants with values greater or smaller
than 4 SDs from its mean value were considered outliers and were removed. To determine if outliers
had a significant effect on our findings we performed a sensitivity analysis and observed few
differences (or slightly more significant), if any, in results when including outliers (eTable 1 in the
Supplement).
Dementia Diagnosis
Participants in ADNI were classified as cognitively normal controls (CN) or having significant memory
concerns (SMC), MCI, ormild clinical AD. Criteria for classificationwere as follows:Mini-Mental State
Examination score range (range, 0 [worst] to 30 [best]) for CN andMCI was 24 to 30, and for ADwas
20 to 26; and overall Clinical Dementia Rating score (range for each, 0 [best] to 3 [worst]) for CNwas
0, forMCIwas 0.5with amandatory requirement ofmemory box score of 0.5 or greater, and for AD
was 0.5 or 1.15 Cognitively normal controls did not have any significant impairment in cognition or
activities of daily living. Participants with SMC had normal cognition and no significant impairment in
activities of daily living, but had a score of 16 or more on the first 12 items of the self-report version
of the Cognitive Change Index (range, 12 [no change] to 60 [severe change]).16 Participants with MCI
had cognitive impairments in memory and/or other domains but were able to perform activities of
daily living and did not qualify for a diagnosis of dementia.15 Participants with AD had to meet the
National Institute of Neurological and Communicative Disorders and Stroke–AD and Related
Disorders Association criteria for probable AD.17 Participants from the ADNI-1 cohort with MCI were
all classified as late MCI, with a memory impairment approximately 1.5 SD below education-adjusted
norms. In the ADNI-GO and ADNI-2 cohort, participants withMCIwere classified as either earlyMCI,
with a memory impairment approximately 1 SD below education-adjusted norms, or late MCI (same
criteria as in ADNI-1). Both ADNI-1 and ADNI-GO and ADNI-2 participantsmet the criteria for amnestic
MCI, but many in the ADNI-GO and ADNI-2 cohort included the earlier stageMCI designation (ie,
early MCI).18
Cognition
Composite scores were used tomeasure memory and executive functioning. Amemory composite
score was created from the following: memory tasks from the Alzheimer Disease Assessment Scale–
cognitive subscale, the Rey Auditory Verbal Learning Test, memory components of theMini-Mental
State Examination, and the Logical Memory task.19 An executive function composite score included
the following: Wechsler Adult Intelligence Scale–Revised Digit Symbol Substitution task and Digit
Span backward task, Trail Making Test Parts A and B, category fluency (animals and vegetables), and
5 clock drawing items. Composite scores have amean of 0 and an SD of 1.20
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Neuroimaging Processing
MRI Scans
Baseline T1-weighted brain MRI scans were acquired using a sagittal 3-dimensional magnetization
prepared rapid gradient echo scans following the ADNI MRI protocol.21,22 As previously detailed,
FreeSurfer, version 5.1, a widely used automatedMRI analysis approach, was used to process MRI
scans and extract whole-brain and region-of-interest (ROI)–based neuroimaging endophenotypes
including volumes and cortical thickness determined by automated segmentation and
parcellation.23-25 The cortical surface was reconstructed tomeasure thickness at each vertex. The
cortical thickness was calculated by taking the Euclidean distance between the gray and white
boundary and the gray and CSF boundary at each vertex on the surface.26-28
PET Scans
Preprocessed fludeoxyglucose (FDG) F 18 (18F) and [18F]florbetapir PET scans (coregistered,
averaged, standardized image and voxel size, and uniform resolution) were downloaded from the
ADNI Laboratory of Neuro Imaging (LONI) site12 as described in previously reportedmethods for
acquisition and processing of PET scans.23,29 For [18F]FDG-PET, scans were intensity normalized
using a pons ROI to create [18F]FDG standardized uptake value ratio (SUVR) images. For
[18F]florbetapir PET, scans were intensity normalized using a whole cerebellum reference region to
create SUVR images.
CSF Biomarkers
The ADNI generated CSF biomarkers (amyloid-β 1-42, total tau [t-tau], and phosphorylated tau181
[p-tau181]) in pristine aliquots of 2401 ADNI CSF samples using the validated and highly automated
Roche Elecsys electrochemiluminescence immunoassays30,31 and the same reagent lot for each of
these 3 biomarkers. Cerebrospinal fluid biomarker data were downloaded from the ADNI LONI site.12
Statistical Analysis
Statistical analysis was conducted fromNovember 1, 2017, to February 28, 2019. Logistic regression
analysis was performed to explore the diagnostic group differences between AD diagnosis and each
liver functionmarker separately. Age, sex, bodymass index (BMI), and APOE ε4 status were used as
covariates. We performed a linear regression analysis to access the association of liver function
markers with composite scores for memory and executive functioning using age, sex, years of
education, BMI, and APOE ε4 status as covariates. We also performed a linear regression analysis
using age, sex, BMI, and APOE ε4 status as covariates.
ROI-BasedAnalysis of StructuralMRI and PET Scans
Mean hippocampal volumewas used as anMRI-related phenotype. For FDG-PET, a mean SUVR value
was extracted from a global cortical ROI representing regions where patients with AD show
decreased glucosemetabolism relative to CN participants from the full ADNI-1 cohort, normalized to
pons.29 For [18F]florbetapir PET, a mean SUVR value was extracted using MarsBaR from a global
cortical region generated from an independent comparison of ADNI-1 [11C] Pittsburgh Compound B
SUVR scans (regions where AD > CN). We performed a linear regression analysis using age, sex, BMI,
and APOE ε4 status as covariates to evaluate the association of liver function markers with
AD-related endophenotypes fromMRI and PET scans. For hippocampal volume, years of education,
intracranial volume, andmagnetic field strength were added as additional covariates.32
Whole-Brain Imaging Analysis
The SurfStat software package33 was used to perform amultivariable analysis of cortical thickness to
examine the association of liver function markers with brain structural changes on a vertex-by-
vertex basis using a general linear model approach.28 General linear models were developed using
age, sex, years of education, intracranial volume, BMI, APOE ε4 status, andmagnetic field strength as
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covariates. The processed FDG-PET and [18F]florbetapir PET images were used to perform a
voxelwise statistical analysis of the association of liver functionmarkers with brain glucose
metabolism and amyloid-β accumulation across the whole brain using SPM8.34We performed a
multivariable regression analysis using age, sex, BMI, and APOE ε4 status as covariates. In the whole-
brain surface-based analysis, the adjustment for multiple comparisons was performed using the
random field theory correctionmethod with P < .05 adjusted as the level for significance.35-37 In the
voxelwise whole-brain analysis, the significant statistical parameters were selected to correspond
to a threshold of P < .05 (false discovery rate [FDR]–corrected).38
Multiple Testing Correction
Results of the analysis of liver functionmarkers with AD diagnosis groups, cognitive composite
measures, and A/T/N biomarkers for AD separately were corrected for multiple testing using the FDR
with the Benjamini-Hochberg procedure (p.adjust command in R [R Project for Statistical
Computing]).
Results
Study Sample
Our analyses included 1581 ADNI participants (407 CN, 20with SMC, 298with early MCI, 544 with
late MCI, and 312 with AD). Demographic information as well as mean and SD of liver function
markers stratified by clinical diagnosis are presented in eTable 2 in the Supplement.
Diagnostic GroupDifference of Liver FunctionMarkersWith ADDiagnosis
Levels of ALT were significantly decreased in AD compared with CN (odds ratio, 0.133; 95% CI,
0.042-0.422; P = .004) (Table 1), while AST to ALT ratio values were significantly increased in AD
(odds ratio, 7.932; 95% CI, 1.673-37.617; P = .03). There was a trend to suggest that ALT levels were
increased and AST to ALT ratio values were decreased in MCI compared with CN, but these became
nonsignificant after adjustment for multiple comparisons (eTable 3 in the Supplement).
Cognition
After adjusting for multiple comparison correction using FDR, we identified significant associations
of liver function markers with cognition (Table 2). Higher levels of alkaline phosphatase and AST to
ALT ratio were associated with lower memory scores (alkaline phosphatase: β [SE], –0.416 [0.162];
P = .02; AST to ALT ratio: β [SE], –0.465 [0.180]; P = .02) and executive functioning scores (alkaline
phosphatase: β [SE], –0.595 [0.193]; P = .006; AST to ALT ratio: β [SE], –0.679 [0.215]; P = .006).
Higher ALT levels were associated with higher memory scores (β [SE], 0.397 [0.128]; P = .006) and
executive functioning scores (β [SE], 0.637 [0.152]; P < .001), whereas higher AST levels were
associated with higher executive functioning scores (β [SE], 0.607 [0.215]; P = .01).
Table 1. Results of Association of Liver Function Biomarkers
With Alzheimer Disease Diagnosisa
Liver Function Marker Odds Ratio (95% CI) Corrected P Value
Albumin, g/dL 5.789 (0.040-843.993) .49
Alkaline phosphatase, U/L 3.620 (0.844-15.529) .12
ALT, U/L 0.133 (0.042-0.422) .004
AST, U/L 0.229 (0.045-1.175) .12
AST to ALT ratio 7.932 (1.673-37.617) .03
Total bilirubin, mg/dL 1.405 (0.585-3.377) .49
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
a Cognitively normal vs Alzheimer disease. Analyses were adjusted for age, sex,
bodymass index, and APOE ε4 status.
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Biomarkers of Amyloid-β
We used CSF amyloid-β 1-42 levels and a global cortical amyloid deposition measured from amyloid
PET scans as biomarkers of amyloid-β. The regression coefficient of the AST to ALT ratio showed a
negative association with CSF amyloid-β 1-42 levels (β [SE], –0.170 [0.061]; P = .04), indicating that
higher AST to ALT ratio values were associated with CSF amyloid-β 1-42 positivity (Figure 1).
However, there was no significant correlation between liver functionmarkers and global cortical
amyloid deposition.
In the whole-brain analysis using multivariable regressionmodels to determine the association
of liver functionmarkers with amyloid-β loadmeasured from amyloid PET scans on a voxelwise level,
we identified significant associations for 2 liver functionmarkers. Higher ALT levels were significantly
associated with reduced amyloid-β deposition in the bilateral parietal lobes (Figure 2A). Increased
AST to ALT ratio values were significantly associated with increased amyloid-β deposition in the
bilateral parietal lobes and right temporal lobe (Figure 2C).
Biomarkers of Fibrillary Tau
We used CSF p-tau levels as a biomarker of fibrillary tau. We investigated the association of liver
functionmarkers with CSF p-tau, adjusting for APOE ε4 status as a covariate. Higher AST to ALT ratio
values were associated with higher CSF p-tau values (β [SE], 0.175 [0.055]; P = .02) (Figure 1).
Biomarkers of Neurodegeneration or Neuronal Injury
We used structural atrophymeasured fromMRI scans, brain glucosemetabolism from FDG-PET
scans, and CSF t-tau levels as biomarkers of neurodegeneration or neuronal injury.
Table 2. Results of Association of Liver Function BiomarkersWith Composite Cognitive PerformanceMeasuresa
Liver Function Marker
Memory Composite Score Executive Function Composite Score
β (SE) Corrected P Value β (SE) Corrected P Value
Albumin, g/dL −0.872 (0.576) .17 −0.203 (0.689) .77
Alkaline phosphatase, U/L −0.416 (0.162) .02 −0.595 (0.193) .006
ALT, U/L 0.397 (0.128) .006 0.637 (0.152) <.001
AST, U/L 0.339 (0.180) .09 0.607 (0.215) .01
AST to ALT ratio −0.465 (0.180) .02 −0.679 (0.215) .006
Total bilirubin, mg/dL −0.068 (0.103) .61 −0.066 (0.123) .65
Abbreviations: ALT, alanine aminotransferase; AST,
aspartate aminotransferase.
a Analyses were adjusted for age, sex, educational
level, bodymass index, and APOE ε4 status.
Figure 1. Results ofAssociationof Liver FunctionBiomarkersWithAmyloid, Tau, andNeurodegeneration (A/T/N)
Biomarkers forAlzheimerDisease
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Heat map of q-values of the association between liver
function markers and the A/T/N biomarkers for
Alzheimer disease. P values estimated from linear
regression analyses were corrected for multiple testing
using false discovery rate (q value). White indicates
q > 0.05, red indicates significant positive association,
and green indicates significant negative association.
Aβ indicates amyloid-β; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; CSF, cerebrospinal
fluid; FDG, fludeoxyglucose positron emission
tomography; MRI, magnetic resonance imaging; and
p-tau, phosphorylated tau.
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Brain GlucoseMetabolism
We performed an ROI-based association analysis of liver functionmarkers with a global cortical
glucosemetabolism value measured from FDG-PET scans across 1167 ADNI participants with both
FDG-PET scans andmeasurement of liver functionmarkers. The association analysis including APOE
ε4 status as a covariate identified 2markers as significantly associatedwith brain glucosemetabolism
after controlling formultiple testing using FDR (Figure 1). For ALT, higher levels were associatedwith
increased glucosemetabolism (β [SE], 0.096 [0.030]; P = .02), while for the AST to ALT ratio, higher
ratio values were associated with reduced glucosemetabolism (β [SE], –0.123 [0.042]; P = .03).
In the detailed whole-brain analysis to determine the association of liver functionmarkers with
brain glucosemetabolism on a voxelwise level, increased ALT levels were associatedwith increased
glucosemetabolism in a widespread pattern, especially in the bilateral frontal, parietal, and temporal
lobes (Figure 2B). However, higher AST to ALT ratio valueswere significantly associatedwith reduced
glucosemetabolism in the bilateral frontal, parietal, and temporal lobes (Figure 2D).
Figure 2. DetailedWhole-Brain Voxel-Based Imaging Analysis for Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) to ALT Ratio Levels Using
Positron Emission Tomography (PET) Scans
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3.5
3.0
2.5
2.0
1.5
1.0
0.5
4
3
2
1
0
0
ALT: fluorodeoxyglucose PETB
AST to ALT ratio: [18F] florbetapir PETC
AST to ALT ratio: fluorodeoxyglucose PETD
4
3
2
1
0
4
3
2
1
0
Whole-brain multivariable analysis was performed to visualize the topography of the
association of ALT levels and AST to ALT ratio values with amyloid-β load and glucose
metabolism on a voxelwise level (false discovery rate–corrected P < .05). A, Higher ALT
levels were significantly associated with reduced amyloid-β deposition in the bilateral
parietal lobes. B, Increased ALT levels were significantly associated with increased
glucosemetabolism in a widespreadmanner, especially in the bilateral frontal, parietal,
and temporal lobes. C, Increased AST to ALT ratio values were significantly associated
with increased amyloid-β deposition in the bilateral parietal lobes and the right temporal
lobe. D, Increased AST to ALT ratio values were significantly associated with reduced
brain glucosemetabolism in the bilateral frontal, parietal, and temporal lobes.
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StructuralMRI (Atrophy)
In the investigation of the association of liver functionmarkers with mean hippocampal volumewith
APOE ε4 status as a covariate, we did not identify any significant association with hippocampal
volume after controlling for multiple testing using FDR (Figure 1). Following the detailed whole-brain
surface-based analysis of liver functionmarkers using multivariable regressionmodels to assess
associations with cortical thickness, higher ALT levels were significantly associated with larger
cortical thickness in the bilateral temporal lobes (Figure 3), which showed consistent patterns in the
associations of brain glucosemetabolism.
CSF t-Tau
Higher AST to ALT ratio values were associated with higher CSF t-tau levels (β [SE], 0.160 [0.049];
P = .02) (Figure 1), which showed consistent patterns in the associations of CSF amyloid-β 1-42 or
p-tau levels and brain glucosemetabolism.
Discussion
We investigated the association between serum-based liver functionmarkers and AD diagnosis,
cognition, and AD pathophysiological characteristics based on the A/T/N framework for AD
biomarkers in the ADNI cohort.39 Our findings suggest that the decreased levels of ALT and elevated
AST to ALT ratio that were observed in patients with ADwere associated with poor cognition and
reduced brain glucosemetabolism. We also found that an increased AST to ALT ratio was associated
with lower CSF amyloid-β 1-42 levels, greater amyloid-β deposition, and higher CSF p-tau and t-tau
levels. Furthermore, we observed that decreased levels of ALT were associated with greater
amyloid-β deposition and structural atrophy.
Figure 3. DetailedWhole-Brain Surface-Based Imaging Analysis for Alanine Aminotransferase (ALT) Levels
UsingMagnetic Resonance Imaging (MRI) Scans
0.025.05
0.025.05
P Value for Cluster P Value for Vertex
Awhole-brain multivariable analysis of cortical
thickness across the brain surface was performed to
visualize the topography of the association of ALT
levels with brain structure. Statistical maps were
thresholded using a random field theory for a multiple
testing adjustment to a corrected significance level of
P < .05. The P value for clusters indicates significant
corrected P values with the lightest blue color. Higher
ALT levels were significantly associated with greater
cortical thickness, especially in bilateral
temporal lobes.
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Decreased levels of ALT and increased AST to ALT ratio values were observed in patients with
AD and were associated with lower scores on measures of memory and executive function. Our
findings are comparablewith those of an earlier study that reported increased AST to ALT ratio values
and lower levels of ALT in patients with AD compared with controls, although in that study, the
association between AD and ALT levels did not reach statistical significance.40 Altered liver enzymes
lead to disturbances in liver-associated metabolites including branched-chain amino acids, ether-
phosphatidylcholines, and lipids,41 which we and others show are altered in AD1,42-44 andmay play a
role in disease pathophysiologic characteristics.45 Disturbed energy metabolism is one of the
processes that may explain the observed lower levels of ALT and increased enzyme ratio in
individuals with AD and impaired cognition.3,5 This finding is concordant with our observation that
increased AST to ALT ratio values and lower levels of ALT showed a consistent significant association
with reduced brain glucosemetabolism, particularly in the orbitofrontal cortex and temporal lobes,
areas of the brain implicated in memory and executive function. Brain glucose hypometabolism is an
early feature of AD and cognitive impairment during the prodromal stage.46,47 Moreover, ALT and
AST are key enzymes in gluconeogenesis in the liver and production of neurotransmitters required in
maintaining synapses.48 Alanine aminotransferase catalyzes a reversible transamination reaction
between alanine and α-ketoglutarate to form pyruvate and glutamate, while AST catalyzes a
reversible reaction between aspartate and α-ketoglutarate to form oxaloacetate and glutamate.49
Although exact mechanisms remain unclear, 2 possible mechanisms may explain altered levels of
enzymes in AD. First, reduced ALT levels lead to reduced pyruvate, which is required for glucose
production via gluconeogenesis in the liver and glucose is distributed in various body tissues as an
energy source,50 thus disturbing energy homeostasis. Second, altered levels of ALT and ASTmay
affect levels of glutamate, an excitatory neurotransmitter of the central nervous system involved in
synaptic transmission, which also plays an important role in memory.51
In the case of low glucosemetabolism in the brain, as observed in our current study, less
α-ketoglutarate is available via the tricarboxylic acid cycle that favors glutamate catabolism vs
glutamate synthesis in reversible reaction (catalyzed by AST and ALT).52 Glutamate acts as a
neurotransmitter in approximately two-thirds of the synapses in neocortical and hippocampal
pyramidal neurons and thus is involved in memory and cognition via long-term potentiation.53 In a
sample of healthy adults, plasma ALT and AST levels were significantly positively correlated with
plasma glutamate levels,5,54 which indicates that lower levels of ALT will decrease glutamate levels
in plasma. Based on evidence from earlier studies that peripheral blood levels of glutamate are
positively correlated with levels of glutamate in the CSF55 and studies that reported lower levels of
glutamate in patients with AD compared with controls in both blood56 and brain tissues,36,57-59 we
can infer that lower levels of ALT or AST may affect glutamate levels in AD. In older adults, lower
serum ALT levels are associated with mortality60,61 and are thought to be a biomarker for increased
frailty, sarcopenia, and/or reduced levels of pyridoxine (vitamin B6).
62 Pyridoxine phosphate is a
coenzyme for the synthesis of amino acids, neurotransmitters (eg, serotonin and norepinephrine),
and sphingolipids. Alanine aminotransferase decreaseswith age63 andmay be a sign of hepatic aging.
Glutamate levels also decreasewith increasing age.64 Together with the fact that age is the strongest
risk factor for AD,65 decreasing levels of ALT with age may also indicate a possible biological link
between aging and AD. Nevertheless, further research is needed to determine the exact cause of
reducing ALT levels with age and the pathway through which it can influence neurologic disorders,
including AD.
Increased AST to ALT ratios are observed in individuals with nonalcoholic fatty liver disease,
which is the hepatic manifestation of metabolic syndrome.66 In the FraminghamHeart Study,
nonalcoholic fatty liver disease was associated with smaller total cerebral brain volume even after
adjustment for multiple cardiovascular risk factors.67 Liver dysfunction is also associated with the
development of disease including cardiovascular disease and insulin resistance through disruptions
in glucose and lipid metabolism, key physiological functions of the liver.68,69 Thus, using the AST to
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ALT ratio as a marker for overall metabolic disturbance,5 our study provides evidence of an
association between alteredmetabolic status and AD, cognition, and AD endophenotypes.
In addition to ALT levels and the AST to ALT ratio, elevated levels of alkaline phosphatase were
significantly associated with poor cognition. This is in line with results from the Oxford Project to
Investigate Memory and Aging, which reported increased alkaline phosphatase levels in individuals
with AD and an inverse association with cognition.70 Alkaline phosphatase is an enzyme primarily
expressed in the liver and kidneys as well as in endothelial cells in the brain.71,72 The neuronal form of
alkaline phosphatase plays a role in developmental plasticity and activity-dependent cortical
functions via contributing in γ-aminobutyric acid metabolism.73-76 Changes in plasma levels of
alkaline phosphatase may occur as a result of central nervous system injury.77
Limitations
This study has several limitations. The observational design of this ADNI cohort study limits our ability
tomake assumptions about causality. There is need to evaluate the association of liver enzymeswith
AD in prospective manner. Another limitation of our study is that we did not adjust for alcohol
consumption, which was not available in ADNI. Alcohol consumption is associated with altered liver
enzymes. Instead, we used a well-established surrogate marker of alcohol consumption,
γ-glutamyltransferase. Elevations in γ-glutamyltransferase generally indicate long-term heavy
drinking rather than episodic heavy drinking.78 Our key findings remained significant after
adjustment for γ-glutamyltransferase and statin use (eTable 4, eTable 5, and eFigure in the
Supplement). However, given the associations with liver function measures and A/T/N biomarkers
for AD, it appears that liver functionmay play a role in the pathogenesis of AD, but limitations should
be taken into account before further extrapolating our findings.
Conclusions
This study’s results suggest that altered liver functionmarkers are associated with AD diagnosis and
impaired memory and executive function as well as amyloid-β, tau, and neurodegenerative
biomarkers of AD pathophysiological characteristics. These results are, to our knowledge, the first to
show an association of peripheral markers of liver functioning with central biomarkers associated
with AD. Although our results suggest an important role of liver functioning in AD pathophysiological
characteristics, the causal pathways remain unknown. The liver-brain biochemical axis of
communication should be further evaluated inmodel systems and longitudinal studies to gain deeper
knowledge of causal pathways.
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Lin, MD; and Lisa Ravdin, PhD. University of South Florida Health Byrd Alzheimer’s Institute: Amanda Smith, MD;
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DOD ADNI investigators include Part A: Leadership and Infrastructure Principal Investigator: Michael W. Weiner,
MD, University of California, San Francisco; ATRI PI and Director of Coordinating Center Clinical Core: Paul Aisen,
MD, University of Southern California; Executive Committee: Michael Weiner, MD, University of California San
Francisco; Paul Aisen, MD, University of Southern California; Ronald Petersen, MD, PhD, Mayo Clinic, Rochester;
Robert C. Green, MD, MPH, Brigham andWomen’s Hospital/Harvard Medical School; Danielle Harvey, PhD,
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Southern California; Michael Donohue, PhD, University of Southern California; Devon Gessert, BS, University of
Southern California; Kelly Harless, BA, University of Southern California; Jennifer Salazar, MBS, University of
Southern California; Yuliana Cabrera, BS, University of Southern California; SarahWalter, MSc, University of
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Medical Center; Thomas Neylan, MD, University of California San Francisco; Jacqueline Hayes, University of
California San Francisco; Shannon Finley, University of California San Francisco; Biostatistics Core Leaders and Key
Personnel: Danielle Harvey, PhD, University of California Davis (Core PI); Michael Donohue, PhD, University of
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Matt Senjem, MS, Mayo Clinic; Kejal Kantarci, Mayo Clinic; ChadWard, Mayo Clinic; PET Core Leaders and Key
Personnel: William Jagust, MD, University of California Berkeley (Core PI); Robert A. Koeppe, PhD, University of
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Leaders: John C. Morris, MD,Washington University, St Louis; Nigel J. Cairns, PhD, FRCPath, Washington
University, St Louis; Erin Householder, MS, Washington University, St Louis; Biomarkers Core Leaders and Key
Personnel: Leslie M. Shaw, PhD, Perelman School of Medicine, University of Pennsylvania; John Q. Trojanowki, MD,
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Personnel: Andrew J. Saykin, PsyD, Indiana University; TatianaM. Foroud, PhD, Indiana University; Steven Potkin,
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Sungeun Kim, PhD, Indiana University; Kwangsik Nho, PhD, Indiana University; Initial Concept Planning &
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Medical Center: Anton P. Porsteinsson, MD (director); Bonnie Goldstein, MS, NP (coordinator); and Kimberly S.
Martin, RN. University of California, Irvine: Steven G. Potkin, MD; Adrian Preda, MD; and Dana Nguyen, PhD.
Medical University of South Carolina: Jacobo Mintzer, MD, MBA; Dino Massoglia, MD, PhD; and Olga Brawman-
Mintzer, MD. Premiere Research Inst (Palm Beach Neurology): Carl Sadowsky, MD;Walter Martinez, MD; and
Teresa Villena, MD. University of California, San Francisco: William Jagust MD; Susan Landau PhD; Howard Rosen,
MD; and David Perry. Georgetown University Medical Center: Raymond Scott Turner, MD, PhD; Kelly Behan; and
Brigid Reynolds, NP. Brigham andWomen’s Hospital: Reisa A. Sperling, MD; Keith A. Johnson, MD; and Gad
Marshall, MD. Banner Sun Health Research Institute: Marwan N. Sabbagh, MD; Sandra A. Jacobson, MD; and
Sherye A. Sirrel, MS, CCRC. Howard University: Thomas O. Obisesan, MD, MPH; SabaWolday, MSc; and Joanne
Allard, PhD. University of Wisconsin: Sterling C. Johnson, PhD; J. Jay Fruehling, MA; and Sandra Harding, MS.
University of Washington: Elaine R. Peskind, MD; Eric C. Petrie, MD, MS; and Gail Li, MD, PhD. Stanford University:
Jerome A. Yesavage, MD; Joy L. Taylor, PhD; Ansgar J. Furst, PhD; and Steven Chao, MD. Cornell University:
Norman Relkin, MD, PhD; Gloria Chiang, MD; and Lisa Ravdin, PhD.
ADNI Depression: Part A: Leadership and Infrastructure Principal Investigator: Scott Mackin, PhD, University of
California San Francisco; ATRI PI and Director of Coordinating Center Clinical Core: Paul Aisen, MD, University of
Southern California; Rema Raman, PhD, University of Southern California. Executive Committee: Scott Mackin,
PhD, University of California San Francisco; Michael Weiner, MD, University of California San Francisco; Paul Aisen,
MD, University of Southern California; Rema Raman, PhD, University of Southern California; Clifford R. Jack Jr, MD,
Mayo Clinic, Rochester; Susan Landau, PhD, University of California Berkeley; Andrew J. Saykin, PsyD, Indiana
University; Arthur W. Toga, PhD, University of Southern California; Charles DeCarli, MD, University of California
Davis; Robert A. Koeppe, PhD, University of Michigan; Data and Publication Committee: Robert C. Green, MD,
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Personnel: Scott Mackin, PhD, University of California San Francisco; Craig Nelson, MD, University of California San
Francisco; David Bickford, BA, University of California San Francisco; Meryl Butters, PhD, University of Pittsburgh;
andMichelle Zmuda, MA, University of Pittsburgh.
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